iBio Inc (IBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
December 2018
49
About the Report
About the Report
Summary
iBio Inc (iBio) is a biotechnology company that develops and manufactures plant made pharmaceutical products. The company provides products such as biotherapeutics and vaccines. It has its applications in ibiolaunch platform, which is a transformative technology for the production of monoclonal antibodies, other therapeutic proteins and vaccines. iBio is developing therapeutic product for the treatment of idiopathic pulmonary fibrosis, systemic scleroderma and other fibrotic diseases, and others. The company's IBIO-CFB03 is helpful for the treatment of idiopathic pulmonary fibrosis, fibrotic diseases and systemic sclerosis, among others. It collaborates with medical universities for its research and development activities. iBio is headquartered in New York, the US.
iBio Inc (IBIO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
iBio Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
iBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
iBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
iBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
iBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
iBio Inc, Medical Devices Deals, 2012 to YTD 2018 10
iBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
iBio Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
iBio Enters into Agreement with AzarGen Biotechnologies 13
Texas A&M University Enters into Agreement with iBio 14
iBio Amends Agreement with Medical University of South Carolina 15
Ibio Enters Into Agreement With GE Healthcare To Commercialize Plant-Based Technologies 16
iBio Enters into Agreement with Novici Biotech 17
Licensing Agreements 18
iBio Amends Licensing Agreement with US University 18
iBio Enters into Licensing Agreement with University of Pittsburgh 19
iBio Enters Into Licensing Agreement With Caliber Biotherapeutics 20
iBio Enters into Licensing Agreement with Caliber Biotherapeutics 22
iBio Extends Licensing Agreement with Fraunhofer 23
iBio Extends its Licensing Agreement with Bio-Manguinhos 24
Equity Offering 25
iBio Raises USD16 Million in Public Offering of Shares 25
iBio Raises USD4.5 Million in Public Offering of Shares 26
iBio to Raise Funds in Public Offering of Shares 27
iBio Raises USD1 Million in First Tranche of Private Placement of Shares 28
iBio Raises USD4 Million in Second and Final Tranche of Private Placement of Shares 30
iBio Raises USD2.2 Million in First Tranche of Private Placement of Shares 31
iBio Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 32
iBio Raises USD0.9 Million in Private Placement of Shares up on Exercise of Warrants 33
iBio Plans to Raise up to USD15 Million in Private Placement of Shares 34
iBio Raises USD10 Million in Private Placemet of Shares 35
iBio Raises USD0.5 Million in First Tranche of Private Placement of Shares 36
Ibio Completes Public Offering Of Units For USD 4 Million 37
iBio, Biotechnology Company, Completes Public Offering Of Common Stock For USD 10 Million 38
iBio Inc-Key Competitors 39
iBio Inc-Key Employees 40
iBio Inc-Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Legal and Regulatory 42
Nov 06, 2017: iBio Initiates Litigation Against Fraunhofer-Gesellschaft in Delaware Chancery Court 42
Product News 43
Mar 14, 2018: iBio Selects Lead Candidate for its Fibrosis Therapeutics Program 43
03/14/2018: iBio Selects Lead Candidate for its Fibrosis Therapeutics Program 44
Mar 07, 2018: iBio Expands Antibody Development and Production Services to Include Fc Fusion Therapeutics 45
Other Significant Developments 46
Oct 30, 2017: iBio CDMO President to Co-Chair South African Molecular Pharming Conference 46
May 04, 2017: iBio Provides Corporate Update at Annual Shareholders Meeting 47
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49
List of Figure
List of Figures
iBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
iBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
iBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
iBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
iBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
iBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
iBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
iBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
iBio Inc, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
iBio Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
iBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
iBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
iBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
iBio Inc, Deals By Therapy Area, 2012 to YTD 2018 9
iBio Inc, Medical Devices Deals, 2012 to YTD 2018 10
iBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
iBio Enters into Agreement with AzarGen Biotechnologies 13
Texas A&M University Enters into Agreement with iBio 14
iBio Amends Agreement with Medical University of South Carolina 15
Ibio Enters Into Agreement With GE Healthcare To Commercialize Plant-Based Technologies 16
iBio Enters into Agreement with Novici Biotech 17
iBio Amends Licensing Agreement with US University 18
iBio Enters into Licensing Agreement with University of Pittsburgh 19
iBio Enters Into Licensing Agreement With Caliber Biotherapeutics 20
iBio Enters into Licensing Agreement with Caliber Biotherapeutics 22
iBio Extends Licensing Agreement with Fraunhofer 23
iBio Extends its Licensing Agreement with Bio-Manguinhos 24
iBio Raises USD16 Million in Public Offering of Shares 25
iBio Raises USD4.5 Million in Public Offering of Shares 26
iBio to Raise Funds in Public Offering of Shares 27
iBio Raises USD1 Million in First Tranche of Private Placement of Shares 28
iBio Raises USD4 Million in Second and Final Tranche of Private Placement of Shares 30
iBio Raises USD2.2 Million in First Tranche of Private Placement of Shares 31
iBio Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 32
iBio Raises USD0.9 Million in Private Placement of Shares up on Exercise of Warrants 33
iBio Plans to Raise up to USD15 Million in Private Placement of Shares 34
iBio Raises USD10 Million in Private Placemet of Shares 35
iBio Raises USD0.5 Million in First Tranche of Private Placement of Shares 36
Ibio Completes Public Offering Of Units For USD 4 Million 37
iBio, Biotechnology Company, Completes Public Offering Of Common Stock For USD 10 Million 38
iBio Inc, Key Competitors 39
iBio Inc, Key Employees 40
iBio Inc, Other Locations 41
iBio Inc, Subsidiaries 41
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.